аЯрЁБс>ўџ OQўџџџPџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџьЅС@ №Пы2bjbjюFюF .:Œ,Œ,Qџџџџџџˆ,44444h$,Ь"˜ЎЎЎЎЎЎЎ"""""""$р#R2&Ъ5"QЎЎ5"ЎЎ†"yyyЎЎ"y"yyV Г!ЎŒ р…Э5МъХ4"/! у!,œ"0Ь";!xќ&)Fќ&Г!,,Г!ќ&Ч!ЎЬЬy˜Є<ЫЎЎЎ5"5",,„А „o ,,А NEWS RELEASE Release Date:  Embargoed until 00.01 GMT, Wednesday 4th May 2005 Issued on behalf of Servier Laboratories Ltd ProtelosЎ significantly reduces non vertebral fracture risk in postmenopausal women with osteoporosis The results of the TROPOS (Treatment of Peripheral Osteoporosis) study, published today in the Journal of Clinical Endocrinology and Metabolism show that strontium ranelate (ProtelosЎ) significantly reduces the risk of all non vertebral and, in a high risk group, hip fractures over three years.1 The study demonstrated the following results: 16% risk reduction in non vertebral fracture (p=0.04)1 19% risk reduction in major fragility fractures (hip, wrist, pelvis & sacrum, ribs & sternum, clavicle and humerus)(p=0.031)1 36% risk reduction in hip fracture in a high risk elderly population (age e" 74 years and T score d" -3)(p=0.046)1 8.2% increase in bone mineral density at the femoral neck (p<0.001)1 In addition, ProtelosЎ was also shown to reduce vertebral fracture by 39% (p<0.001)1, a result which reinforces the previous finding published in the Spinal Osteoporosis Therapeutic Intervention (SOTI) study,2 where vertebral fracture risk was shown to be reduced by 41% over three years and by 49% in the first year.2 The double-blind, placebo-controlled study was conducted over five years in 5,091 postmenopausal women with osteoporosis with a main statistical analysis over three years of treatment.1 In line with international recommendations, calcium and vitamin D supplements were given to patients before and during the study; patients were then randomised to receive placebo or ProtelosЎ.1  ProtelosЎ was well tolerated throughout the study, especially at the upper gastrointestinal level, with an incidence of adverse events not significantly different to placebo.1 Professor Juliet Compston of Addenbrooke’s Hospital, Cambridge and a lead author on TROPOS said, “These results are encouraging as they demonstrate that Protelos has a clear benefit across the full spectrum of fractures.  The data add to the growing weight of evidence supporting the use of Protelos as a first line treatment for postmenopausal osteoporosis.” It has been estimated that in England and Wales, approximately 180,000 symptomatic osteoporotic fractures occur each year, with around 50% of these fractures occurring in women over the age of 75 years.3  The combined social care and medical costs for treating osteoporotic fractures is estimated to be at least Ѓ1.7 billion annually in the UK.4 Professor Tim Spector, TROPOS trialist added, “Hip fractures are very costly to treat and have a greater impact on patients’ health and quality of life than other fractures.  Protelos is one of the only osteoporosis therapies to be studied in such depth in an elderly population and it will be interesting to see how this data will be interpreted when NICE review Protelos next year.” Protelosт№ was launched in the UK in November 2004 and is licensed for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures.  ProtelosЎ is the first in a new class of drug treatments called Dual Action Bone Agents (DABAs), and is the only osteoporosis drug to simultaneously increase bone formation and decrease bone resorption.  ProtelosЎ is a 2g sachet of tasteless powder to be dissolved in a glass of water.  It should be taken once daily preferably at bedtime and at least two hours after eating. Editor’s notes The TROPOS study was conducted in 75 centres in 11 European countries and Australia. Servier Laboratories is an independently owned pharmaceutical company based in France. Servier has over 16,000 employees worldwide including 2,500 in research and development. Servier’s commitment to research has resulted in one of the most active product pipelines in the industry. The Company invests over 25% of annual turnover into research, a figure double the industry average. Servier’s contribution to improving the management of disease in the UK remains a key priority, with products in the osteoporosis, cardiovascular and diabetes therapy areas. Osteoporosis is a progressive bone disease characterised by a loss of bone density and deterioration of the bone structure.  This results in increased bone fragility and susceptibility to fracture.5 At least one in three adult women and one in 12 adult men aged 50 and over will sustain one or more vertebral, hip or other fractures.6 At least one in three adult women and one in 12 adult men aged 50 and over will sustain one or more vertebral, hip or other fractures.4 References Reginster JY, Seeman E et al. Journal of Clinical Endocrinology and Metabolism 2005; 90(5):2816-2822. Meunier PJ, Roux C, Seeman E et al.  New England Journal of Medicine 2004; 350: 459-468. National Institute for Clinical Excellence.  Technology Appraisal Guidance 87.  Issued January 2005. National institute for Clinical Excellence.  Final appraisal determination: bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporosis fragility fractures in postmenopausal women.  July 2004.  CEO}~†‡фх  хЪЖЁЖŒt\C\+ŒtŒtŒ.hXhX5CJOJQJ\^JaJnH tH 1hXhX5CJH*OJQJ\^JaJnH tH .hXhX5CJOJQJ\^JaJnH tH .hXhX5CJOJQJ\^JaJnH tH (hXhXCJOJQJ^JaJnH tH )hXhX5H*OJQJ\^JnH tH &hXhX5OJQJ\^JnH tH 4hXhX56CJOJQJ\]^JaJnH tH 4hXhX56CJOJQJ\]^JaJnH tH  OP}~фх< = u є P м о ЎЏ-.опGHїђцоожжђђђЮЮЮЮђЦЦЦЦЦЦЦЦ$a$gdX & FgdX$a$gdXdhgdX $Є№Є<@&gdXgdX$@&gdXы2§    D u › œ r s t ё ђ ѓ  . 2 J L N ж и к м о  шгшгЛгЅгЅгvгvгaгaгvгvгLг(hXhXCJOJQJ^JaJnH tH (hXhXOJQJ^JmH nH sH tH 0hXhXCJOJQJ^JaJmH nH sH tH +hXhXCJH*OJQJ^JaJnH tH +hXhXCJH*OJQJ^JaJnH tH .hXhX6CJOJQJ]^JaJnH tH (hXhXCJOJQJ^JaJnH tH .hXhX5CJOJQJ\^JaJnH tH  „ †   %&?@Ќ­gh'(),68мно@F Ёб$NPsuыеыНыНыНыНыеыеыеыЇыЇыЇ’ЇеыzыЇыеыzыdыЇые+hXhXCJH*OJQJ^JaJnH tH .hXhX6CJOJQJ]^JaJnH tH (hXhXCJOJQJ^JaJnH tH +hXhXCJH*OJQJ^JaJnH tH .hXhX5CJOJQJ\^JaJnH tH +hXhXCJH*OJQJ^JaJnH tH (hXhXCJOJQJ^JaJnH tH 'HЂЃ$%(~/џ­ќ§…†‘їPЕћ11в1їїїїїїьсссссьїмдЬОЬЬЬЬ$$ & F@&a$gdX & FgdX$@&gdXgdX $ & Fa$gdX $$@&a$gdX$a$gdXu(rtњћќ§ƒ„†‘ЏпрфцшїыбыЛыЛЃ‰ыЛыбpTpTp8p6hXhX5CJOJQJ\^JaJmH nH sH tH 6hXhX6CJOJQJ]^JaJmH nH sH tH 0hXhXCJOJQJ^JaJmH nH sH tH 2hXhX5CJKH$OJQJ\^JaJnH tH .hXhX6CJOJQJ]^JaJnH tH +hXhXCJH*OJQJ^JaJnH tH 2hXhX5CJKH$OJQJ\^JaJnH tH (hXhXCJOJQJ^JaJnH tH їBFPЕћ00}1~1Ђ1Ѓ1Б1В1в1хЫБšljlQlQ8Ql0hXhX>*B*CJOJQJ^JnH phџtH 1jhXhXCJOJQJU^JaJnH tH U(hXhXCJOJQJ^JaJnH tH 0hXhXCJOJQJ^JaJmH nH sH tH ,hXhXCJKH$OJQJ^JaJnH tH 2hXhX5CJKH$OJQJ\^JaJnH tH 2hXhX6CJKH$OJQJ]^JaJnH tH 4hXhXCJKH$OJQJ^JaJmH nH sH tH Royal College of Physicians, Bone and Tooth Society of Great Britain. Osteoporosis: Clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. London: RCP, 2001: www.rcplondon.ac.uk/pubs/wp_osteo_update.htm (last accessed 17 October 2003). National Osteoporosis Society website.  What is Osteoporosis?  What is it?   HYPERLINK "http://www.nos.org.uk/" www.nos.org.uk (last accessed February 2005). For further information, please contact: Michelle Cammack Athena Medical PR                                                     Tel: 020 8956 2204 Email: michelle@athenamedicalpr.comElizabeth Walters Athena Medial PR Tel: 020 8956 2872 Email: Elizabeth@athenamedicalpr.com в1г1ќ1 2T2g2‹22Ў2С2ц2ч2ш2щ2їьраарррррvqqgdXYkd$$Ifж0”џ8о ІЇі6жџџжџџжџџжџџ2ж2ж l4жaіpжџџџџ$„цћ$If]„цћa$gdX $$Ifa$gdX $dha$gdX$a$gdX в1г1ќ1ц2ч2щ2ъ2ы2ыгыФыЏЋhX(hXhXCJOJQJ^JaJnH tH hXhXCJaJnH tH .hXhX5CJOJQJ\^JaJnH tH (hXhXCJOJQJ^JaJnH tH щ2ъ2ы2њјgdX,1hА‚. АЦA!А"А# $ %ААФАФ Ф…$$If–”џ!vh5жЄ5жІ#vЄ#vІ:V і6і5жІ5жЇ2ж2ж l4ж pжџџџџœ@@ёџ@ NormalCJ_HaJmH sH tH V`V X Heading 1$@&"5CJKH$OJQJ\^JaJtH P`"P X Heading 2$@&56OJQJ\]^JtH Z`2Z X Heading 3$Є№Є<@&5CJOJQJ\^JaJtH DA@ђџЁD Default Paragraph FontVi@ѓџГV  Table Normal :V і4ж4ж laі (kєџС(No List 4U`Ђё4 X Hyperlink >*phџX>`X XTitle$dЄ№Є<a$5CJ OJQJ\^JaJ tH PQ`P X Body Text 35CJOJQJ\^JaJtH Q:џџџџ OP}~фх<=uєfЌ­ьэkl…†р с b c ƒ „ “ щ šjgh№ёќbЛ f—89bsКЭё'LMNOPS0€€˜0€(0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜ 0€˜ 0€˜ 0€˜ 0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€˜0€0€€˜ 0€„ ˜ 0€„ ˜ 0€„ ˜ 0€„ ˜ 0€„ 0€€˜0€g˜0€g0€€˜ 0€ё 0€€˜ 0€b˜ 0€b˜ 0€b˜ 0€b˜0€€˜0€€Љ0€€Љ0€€Љ0€€Љ0€€ Љ0€€Љ0€€Љ0€€Љ0€€ ™0€€ ˜0€€\~00\~00\>00 OP}~фх<=uєfЌ­ьэkl…†р с b c ƒ „ “ щ šjgh№ёќbЛ f—89bsКЭё'LMNOPS^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N^~00N\~00\~00\~00 \~00 \~00Р€\~00Р€\~00Р€^~00д… uїв1ы2Hв1щ2ы2ы2уQXџŒџџѕД`œbіД`ДљїД`ŒR!јД`є)љД`4“њД`d5“ћД`Є5“ќД`ф5“§Д`D4“ўД`„4“џД`є4“Е`Ф3“Е`„3“Е`$!Е`ф !Е`Є !Е` ѓ Е`!Е`ЬЌ"Е`Œ”8RR  н н 88ЏЏ‡llw55„S     N[[ƒ ƒ ц ц >>ББ’sЊЊ;;“S  _*€urn:schemas-microsoft-com:office:smarttags€country-region€http://www.5iantlavalamp.com/=*€urn:schemas-microsoft-com:office:smarttags €PlaceType€=*€urn:schemas-microsoft-com:office:smarttags €PlaceName€8*€urn:schemas-microsoft-com:office:smarttags€date€h*€urn:schemas-microsoft-com:office:smarttags€City0€http://www.5iamas-microsoft-com:office:smarttagsV*€urn:schemas-microsoft-com:office:smarttags€place€http://www.5iantlavalamp.com/  €10€17€2003€2005€4€5€Day€Month€Year&,b‡S3„ “ ёќ[fbё'PSSщj‘Ѕ†$џџџџџџџџџj а <ИR—џџџџџџџџџ?Dў(=@Фџџџџџџџџџ„h„˜ўЦh^„h`„˜ў56CJOJQJo(‡hˆHЗ№ „ „˜ўЦ ^„ `„˜ў‡hˆH. „p„˜ўЦp^„p`„˜ў‡hˆH. „@ „˜ўЦ@ ^„@ `„˜ў‡hˆH. „„˜ўЦ^„`„˜ў‡hˆH. „р„˜ўЦр^„р`„˜ў‡hˆH. „А„˜ўЦА^„А`„˜ў‡hˆH. „€„˜ўЦ€^„€`„˜ў‡hˆH. „P„˜ўЦP^„P`„˜ў‡hˆH. „h„˜ўЦh^„h`„˜ў‡hˆH. „ „˜ўЦ ^„ `„˜ў‡hˆH. „p„˜ўЦp^„p`„˜ў‡hˆH. „@ „˜ўЦ@ ^„@ `„˜ў‡hˆH. „„˜ўЦ^„`„˜ў‡hˆH. „р„˜ўЦр^„р`„˜ў‡hˆH. „А„˜ўЦА^„А`„˜ў‡hˆH. „€„˜ўЦ€^„€`„˜ў‡hˆH. „P„˜ўЦP^„P`„˜ў‡hˆH.„а„˜ўЦа^„а`„˜ўOJQJo(‡hˆHЗ№ „ „˜ўЦ ^„ `„˜ў‡hˆH. „p„˜ўЦp^„p`„˜ў‡hˆH. „@ „˜ўЦ@ ^„@ `„˜ў‡hˆH. „„˜ўЦ^„`„˜ў‡hˆH. „р„˜ўЦр^„р`„˜ў‡hˆH. „А„˜ўЦА^„А`„˜ў‡hˆH. „€„˜ўЦ€^„€`„˜ў‡hˆH. „P„˜ўЦP^„P`„˜ў‡hˆH.?Dў(‡J џўщj‘P‡J џўj а œ‡J џўџџџџ€|)0‘&JљІSљІ”љІжM0и[31џџџџР‘‘RЦд‘№Nжы0и[31џџџџа‘‘RЦд‘•ёNжы0и[31џџџџЬWФ                          •Я1хXbёLMS–џ@€PPа JPPL>>k k fQ€@€ €@€€0@€`@џџUnknownџџџџџџџџџџџџG‡z €џTimes New Roman5€Symbol3& ‡z €џArial] Arial (W1)Times New Roman"1Œ№аhЋƒ›fЌƒ›fzз *zз *б№ ДД24FF3ƒQ№мH)№џ?фџџџџџџџџџџџџџџџџџџџџџXџџ NEWS RELEASE"Guy's & St. Thomas' Hospital Trust"Guy's & St. Thomas' Hospital Trust   ўџр…ŸђљOhЋ‘+'Гй0Ј˜АМшє <H d p |ˆ˜ ф NEWS RELEASEoEWS#Guy's & St. Thomas' Hospital Trustruy'uy'Normal #Guy's & St. Thomas' Hospital Trustr1y'Microsoft Word 10.0@FУ#@2s МъХ@x6.МъХzзўџеЭеœ.“—+,љЎDеЭеœ.“—+,љЎX hpœЄЌД МФЬд м ѕф#Guy's & St. Thomas' Hospital Trust* Fт  NEWS RELEASE TitleА 8@ _PID_HLINKSфAh&dhttp://www.nos.org.uk/ ўџџџ !"#$%ўџџџ'()*+,-./0123456789ўџџџ;<=>?@AўџџџCDEFGHIўџџџ§џџџLўџџџўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџRoot Entryџџџџџџџџ РFріЯ5МъХN€Data џџџџџџџџџџџџ1Tableџџџџ&'WordDocumentџџџџ.:SummaryInformation(џџџџџџџџџџџџ:DocumentSummaryInformation8џџџџџџџџBCompObjџџџџџџџџџџџџjџџџџџџџџџџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџўџ џџџџ РFMicrosoft Word Document MSWordDocWord.Document.8є9ВqRoot Entryџџџџџџџџ РFPRїyМъХTРData џџџџџџџџџџџџ1Tableџџџџ&'WordDocumentџџџџ.: ўџџџ !"#$%ўџџџ'()*+,-./0123456789ўџџџ;<=>?@AўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџS§џџџўџџџўџџџўџџџRџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџўџџџ ўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџ@hЌ _PID_HLINKS_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayNameфAh&dhttp://www.nos.org.uk/Ц‘fPress releasesVictoria.Vazquez@gstt.nhs.ukVazquez VictoriaSummaryInformation(џџџџџџџџџџџџ:DocumentSummaryInformation8џџџџџџџџ0CompObjџџџџџџџџџџџџjџџџџџџџџџџџџўџ џџџџ РFMicrosoft Word Document MSWordDocWord.Document.8є9ВqўџеЭеœ.“—+,љЎDеЭеœ.“—+,љЎX hpœЄЌД МФЬд м ѕф#Guy's & St. Thomas' Hospital Trust* Fт  NEWS RELEASE Titleи@РШ8